The value of the drugmaker Novo Nordisk jumped by about £9bn on Thursday after research showed that taking its new anti-obesity pill can result in almost as much weight loss as its Wegovy jab.
The Danish company is racing against its US rival Eli Lilly to get a tablet treatment to market. Shares in Novo Nordisk climbed by more than 6% on hopes that it can claw back market share lost to Eli Lilly and cheaper generic versions of GLP-1 drugs.